Replies to post #513732 on Momentum Players

[langlui]

GNBT is getting closer to a cancer vaccine, so if you are in it, click on the 2 links below

GNBT OncUView.tv Interviews Featuring the Antigen Express AE37

Generex Announces OncUView.tv Interviews Featuring the Antigen Express AE37 Breast Cancer Vaccine at ASCO 2012

WORCESTER, Mass. and TORONTO , June 13, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT) announced today that two interviews conducted at the 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago earlier this month featuring the on-going Phase II clinical trial of the Antigen Express AE37 immunotherapeutic breast cancer vaccine are now available for online viewing at OncUView.tv.
Dr. Timothy Vreeland , MD of the San Antonio Military Medical Center made the June 4, 2012 podium presentation at ASCO 2012 of the abstract entitled "From bench to bedside: The use of the li-Key technology to improve helper peptides for clinical use in cancer vaccines" during the session on Developmental Therapeutics — Clinical Pharmacology and Immunotherapy. For this abstract, Dr. Vreeland was recognized with a 2012 Conquer Cancer Foundation of ASCO Merit Award bestowed by the Conquer Cancer Foundation of the American Society of Clinical Oncology and the 2012 Scientific Program Committee. The interview of Dr. Vreeland can be viewed at:
http://www.oncuview.tv/Videos/TabId/79/VideoId/452/Breast-Cancer-And-2012-ASCO-Merit-Award-Winner-Interview-With-Timothy-Vreeland-MD-At-ASCO-2012.aspx

Dr. Elizabeth A. Mittendorf , MD is an Assistant Professor in the Department of Surgical Oncology at the University of Texas MD Anderson Cancer Center and the Principal Investigator for the on-going Phase II clinical trial of the Antigen Express AE37 immunotherapeutic breast cancer vaccine. The interview of Dr. Mittendorf, where she discusses the AE37 trial results presented at ASCO 2012 and the immunotherapeutic treatment of breast cancer generally, can be viewed at:
http://www.oncuview.tv/Videos/TabId/79/VideoId/440/Breast-Cancer-Interview-With-Elizabeth-Ann-Mittendorf-MD-At-ASCO-2012.aspx

[Zardiw]

RGIN and Department of Defense connection:

- The U.S. Department of Defense recently awarded more than $18M in funding to a unit of Lonza Group, Ltd. for the development and commercialization of the therapeutic candidate, PermaDerm for the treatment of severe burns among U.S. troops and civilians. The funding was announced at a conference celebrating advancements in regenerative medicine on November 9th in Walkersville, MD.
- Regenicin, Inc. (OTC Bulletin Board:RGIN.ob - News), has an agreement with Lonza pursuant to which Regenicin has been charged to obtain FDA approval for the commercial sale of PermaDerm. The funding will assist Regenicin and Lonza in advancing the clinical trials to be conducted in connection with the FDA approval process. Regenicin was a presenter at the conference at which the funding was awarded.


z